Research programme: human monoclonal antibodies - XTL Biopharmaceuticals/Dyax
Alternative Names: Human monoclonal antibodies research programme - XTL Biopharmaceuticals/Dyax; Onco-TrimeraXTLLatest Information Update: 03 Oct 2002
Price :
$50 *
At a glance
- Originator Dyax; XTL Biopharmaceuticals
- Developer Dyax Corp.; XTL Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Mycoses
Most Recent Events
- 03 Oct 2002 Discontinued - Preclinical for Cancer in Israel (unspecified route)
- 03 Oct 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 03 Oct 2002 Discontinued - Preclinical for Mycoses in Israel (unspecified route)